Changshan Pharmaceutical: Revenue drops by 15.10% in 2025, stock trading experiences abnormal volatility.

Changshan Pharmaceutical announced that the company's stock price deviated by over 30% in the closing prices from July 15th to 17th, which is considered abnormal fluctuation. In the year 2025, the company's revenue was 875,132.3 million yuan, a decrease of 15.10% year-on-year; net loss was 357,895.6 million yuan, with a basic loss per share of 0.39 yuan/share. The Aibin peptide injection is not yet on the market, the treatment for type 2 diabetes is in the application review stage, the indication for weight loss has been approved but clinical trials have not been conducted, and the company only holds a 51% stake in the R&D entity Changshan Kaijiejian, with uncertain profitability. Investors are reminded to pay attention to risks.